The Latest Breaking News from JNJ

The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally

JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive

Johnson & Johnson is poised to release its fiscal fourth-quarter earnings this month, and analysts project a double-digit profit decline.

Let’s take a look at Barchart’s Bear Call Spread Screener for December 19th:

The healthcare sector is transforming with the adoption of digital technologies, improved productivity, and increasing R&D efforts. Thus, investors could consider quality healthcare innovator stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and Bristol-Myers Squibb (BMY) as portfolio additions for potential gains. Continue reading.

For investors seeking a balanced approach, healthcare ETFs offer a combination of stability and growth potential. Therefore, it might be wise to consider Fidelity MSCI Health Care Index ETF (FHLC), iShares U.S. Healthcare ETF (IYH), and Vanguard Health Care Index Fund ETF Shares (VHT) for a balanced approach. Keep reading….

Johnson & Johnson has underperformed the Nasdaq over the past year, but analysts are moderately optimistic about the stock’s prospects.

Amid ongoing uncertainties surrounding the economy and global power dynamics, market volatility continues to dominate. In such times, investing in fundamentally sound blue-chip stocks, Johnson & Johnson (JNJ), American Express (AXP), and AT&T (T), could offer investors a stable foundation, serving as a buffer against market fluctuations and uncertainty. Read…

Dividend Aristocrats offer stability, reliable income, and risk mitigation, with consistent dividend growth helping to combat uncertain times. Hence, it could be wise to add top Dividend Aristocrats like Johnson & Johnson (JNJ), PepsiCo (PEP), and Kimberly-Clark (KMB) to your portfolio. Read on.